Preventing the occurrence of hospital-acquired pressure ulcers while reducing operational costs is a challenge. You need a solution that achieves the goal of improving patient outcomes while reducing operational costs.
The bed linens and patient gowns that touch a patient’s skin are often seen as housekeeping items, despite our individual healthcare needs. While billions of dollars are spent attempting to prevent pressure ulcers, little attention has been given to the impact bedding and gowns may have on outcomes.
FDA cleared* to prevent the development of pressure ulcers and backed by clinical evidence**, DermaTherapy® is the first and only therapeutic linen system to be granted U.S. Patents. (US 7,816,288 and US 8,283,267)
DermaTherapy® is a strategic supply chain solution that improves outcomes.
DermaTherapy® is also FDA cleared*** for use in the treatment of atopic dermatitis by patients who are susceptible to or may have mild atopic dermatitis, the most common form of eczema.